Clinicopathological characteristics of mucinous adenocarcinoma of the ovary

Gynecologic Oncology

Volumn 113, Issue 3, 2009, Pages 331-334

  Shimada, Muneaki ^a   Kigawa, Junzo ^a   Ohishi, Yoshihiro ^b   Yasuda, Makoto ^c   Suzuki, Mitsuaki ^d   Hiura, Masamichi ^e   Nishimura, Ryuichiro ^f   Tabata, Tsutomu ^g   Sugiyama, Toru ^h   Kaku, Tsunehisa ⁱ  

^a TOTTORI UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^f HYOGO CANCER CENTER   (Japan)

^g MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h IWATE MEDICAL UNIVERSITY   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Clinicopathological characteristics; Complete surgery; Mucinous invasive adenocarcinoma

Indexed keywords

ADENOCARCINOMA; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; OVARY ADENOCARCINOMA; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; SEROUS ADENOCARCINOMA;

ADENOCARCINOMA, MUCINOUS; CASE-CONTROL STUDIES; FEMALE; HUMANS; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67349108374     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.02.010     Document Type: Article

References (19)

1. Ozols R.F. Treatment goals in ovarian cancer. Int. J. Gynecol. Cancer 15 (2005) 3-11
2. Bookman M.A., McGuire W.P., Kilpatrick D., Keenan E., Hogan W.M., Johnson S.W., et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J. Clin. Oncol. 14 (1996) 1895-1902
3. Ansquer Y., Leblanc E., Clough K., Morice P., Dauplat J., Mathevet P., et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma. A French multicenter study. Cancer 91 (2001) 2329-2334
4. Winter III W.E., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., et al. Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 25 (2007) 3621-3627
5. Sugiyama T., Kamura T., Kigawa J., Terakawa N., Kikuchi Y., Kita T., et al. Clinical characteristics of clear cell carcinoma of the ovary. Cancer 88 (2000) 2584-2589
6. Hess V., A'Hern R., Nasiri N., King D.M., Blake P.R., Barton D.P., et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J. Clin. Oncol. 22 (2004) 1040-1044
7. McGuire V., Jesser C.A., and Whittemore A.S. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol. Oncol. 84 (2002) 399-403
8. Seidman J.D., Kurman R.J., and Ronnett B.M. Primary and metastatic mucinous adenocarcinoma in the ovaries. Am. J. Surg. Pathol. 27 (2003) 985-993
9. Borderline ovarian tumor workshop. Bethesda, Maryland, August 27-28, 2003. Hum. Pathol. 35 (2004) 907-960
10. Lee K.R., and Scully R.E. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinoma, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am. J. Surg. Pathol. 24 (2000) 1447-1464
11. Kurman R.J. Blaustein's Pathology of the Female Genital Tract. 5th ed (2002), Springer 846-863
12. Hart W.R. Mucinous tumors of the ovary: a review. Int. J. Gynecol. Pathol. 24 (2005) 4-25
13. Serov S.F., Scully R.E., and Sobin L.H. Histological Typing Of Ovarian Tumors: International Histological Classification Of Tumors No. 9 (1973), World Health Organization, Geneva
14. Malkasian Jr. G.D., Melton III L.J., O'Brein P.C., and Greene M.H. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am. J. Obstet. Gynecol. 149 (1984) 274-284
15. Harrison M.L., Jameson C., and Gore M.E. Mucinous ovarian cancer. Int. J. Gynecol. Cancer 18 (2008) 209-214
16. Makar A.P., Baekelandt M., Trope C.G., and Kristensen G.B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol. Oncol. 56 (1995) 175-180
17. Pectasides D., Fountzilas G., Aravantinos G., Kalofonos H.P., Efstathiou E., Salamalekis E., et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic cooperative oncology group experience. Gynecol. Oncol. 97 (2005) 436-441
18. Pisano C., Greggi S., Tambaro R., Losito S., Iodice F., Di Maio M., et al. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. Anticancer Res. 25 (2005) 3501-3506
19. Sato S, Itamochi H, Kigawa J, Oishi T, Shimada M, Sato S, Naniwa J, Uegaki K, Nonaka M, Terakawa N. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: A potential treatment strategy. Cancer Sci 2009;100:546--51.